The Prognostic Significance of the Neutrophil-to-Lymphocyte Ratio in Patients with Multiple Myeloma: A Pilot Study

Medetalibeyoğlu, Alpay; Akyüz, Nur; Bayrakdar, Sena; Altunkaynak, Mustafa; Akpınar, Timur Selçuk; Taşçıoğlu, Cemil

doi:10.26650/jarhs2020-796997

Cited by 1 publication

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increased NLR levels of autologous‐transplanted patients with myeloma at day 100 (after reinfusion) also predicted reduced survival 12 . However, there are studies in the literature suggesting that the increased NLR may not be able to predict survival in patients with multiple myeloma 32,33 . In our study, increased NLR group presented significantly longer OS and PFS.…”

Section: Discussioncontrasting

confidence: 66%

See 1 more Smart Citation

The effect of haemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma

Solmaz

Uzun

Sevindik

et al. 2022

Int J Lab Hematology

View full text Add to dashboard Cite

Introduction In multiple myeloma cases, a variety of prognostic parameters have been identified, which contain the Durie‐Salmon classification and the international staging system (ISS) that takes the serum ß2 microglobulin and albumin levels, platelet‐to‐lymphocyte ratio (PLR), neutrophil‐to‐lymphocyte ratio (NLR), and monocyte‐to‐lymphocyte ratio (MLR). This study investigates the effect of haemoglobin, albumin, lymphocyte and platelet (HALP) score which is a marker of inflammation status and nutrition, at the time of diagnosis for the patients with multiple myeloma on prognosis. Methods A total of 200 multiple myeloma patients with HALP scores calculated from serum haemoglobin, albumin, lymphocyte count and platelet levels at the time of diagnosis were retrospectively examined. The effect of HALP score on overall survival (OS) and progression‐free survival and its relationship between the previously evaluated prognostic parameters were investigated. Results The optimal cut‐off value with the ROC curves for the HALP score was 28.8. The patients were divided into two groups according to the optimal value of the HALP score (low‐score group: HALP ≤28.8 [n: 134] and high‐score group HALP >28.8 [n: 66]). In the group with the high HALP score, the OS was statistically longer than the low HALP score group (84 months and 53 months; p = 0.0001). In addition, when the effects of NLR, PLR, HALP score and ISS stage on OS were examined by multivariate analysis, all these markers were found to be statistically significant predictors. Conclusions HALP score may be a valuable prognostic marker for patients with multiple myeloma.

show abstract

Section: Discussioncontrasting

confidence: 66%

“…12 However, there are studies in the literature suggesting that the increased NLR may not be able to predict survival in patients with multiple myeloma. 32,33 In our study, increased NLR group presented significantly longer OS and PFS.…”

Section: Discussionsupporting

confidence: 53%